CHICAGO, Dec. 5 /PRNewswire/ -- Early clinical experience with the FDA cleared Visica 2(TM) Treatment System from Sanarus Medical confirms the effectiveness of ultrasound guided cryoablation to completely eradicate small, unifocal Invasive Ductal Breast Cancer (IDC). Initial data from this multi-center study was presented at the 94th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 29 - December 5, 2008.
The study, "New Findings on Contrast-enhanced Magnetic Resonance Imaging, the "Black Hole" and "Cryohalo" are Markers for the Efficacy of Ultrasound-guided Cryoablation of Small Unifocal Invasive Ductal Breast Cancer," presented by Gary Levine, MD, Director of Breast Imaging at Hoag Breast Care Center in Newport Beach, Calif., was designed to evaluate the ability of breast contrast enhanced MRI to assess the effectiveness of ultrasound guided cryoablation for the local treatment of small, unifocal IDC.
"With a large body of evidence demonstrating the ability of cryoablation to destroy cancerous and noncancerous tumors of the liver, prostate, kidney and breast, the gating factor for the treatment of breast cancer tumors was the ability to visualize the extent of the tumor in advance and confirm target destruction post-procedure," said Dr. Levine. "We are very encouraged that our preliminary results demonstrate that in selected early IDC breast cancers, cryoablation with MRI confirmation may offer the same therapeutic benefit as lumpectomy with less morbidity, improved cosmesis and less cost."
Patients with newly diagnosed IDC underwent an "early" pre-ablation CEMRI
to establish its MR enhancement pattern. Ultrasound-guided cryoablation was
then performed using a Visica Treatment System to ablate the malignant tumor
and a margin of surrounding tissue. A "delayed" CEMRI was performed
approximately four weeks post-ablation followed by a standard surg
|SOURCE Sanarus Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved